Does anyone know if the exec team has the garden variety common stock/stock options, or those that happen to have a weighted average exercise price of $8,771.60 per share?
By the by, 100% chance I would believe it if someone told me Sam wrote these paragraphs.
The table above excludes the following potentially dilutive securities as of January 31, 2018:
• 129 shares issuable upon the exercise of stock options at a weighted average exercise price of $8,771.60 per share;
• 7.0 million shares issuable upon the exercise of outstanding warrants at a weighted average exercise price of $3.14 per share;
• 76 shares reserved for future issuance under our 2009 Equity Incentive Plan, as amended;
• 500,000,000 Warrant Shares underlying the Series D warrants to be issued hereunder; and
• 285 unvested restricted shares.
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following tables contain information regarding the beneficial ownership of our common stock as of January 31, 2018, held by: (i) each of our directors; (ii) each of our named executive officers in the Summary Compensation Table; (iii) all of our directors and executive officers as a group; and (iv) each person or group known by us to own beneficially more than 5% of the outstanding common stock. We are not aware of any 5% or more holders of our Common Stock as of January 31, 2018 except as set forth below. The information set forth in the table below excludes shares issuable upon exercise of our outstanding warrants held by certain investors that are presently exercisable, subject to limitations on exercisability for more than 4.9% or 9.9% of our outstanding shares of common stock, depending upon the particular investor. Except as indicated in the footnotes below, the address of the persons or groups named below is c/o Delcath Systems, Inc., 1633 Broadway, Suite 22C, New York, New York 10019.
Directors and Officers
Shares
Beneficially
Owned (1)
Name of Beneficial Owner: Number Percent
Named Executive Officers and Directors:
Jennifer K. Simpson, Ph.D.(2) 132 *
John Purpura, M.S.(3) 106 *
Barbra C. Keck, M.B.A.(4) 73 *
Simon Pedder, PhD.(5) — *
Roger G. Stoll, Ph.D.(6) 9 *
William D. Rueckert(7) 17 *
Marco Taglietti, M.D.(8) 49 *
All directors and executive officers as a group (7 people)(9): *
* Less than 1%
(1) Except as indicated in these footnotes: (i) the persons named in this table have sole voting and investment power with respect to all shares of common stock beneficially owned; (ii) the number of shares beneficially owned by each person as of January 31, 2018, includes any vested and unvested shares of restricted stock and any shares of common stock that such person or group has the right to acquire within 60 days of January 31, 2018, upon the exercise of stock options; and (iii) for each person or group included in the table, percentage ownership is calculated by dividing the number of shares beneficially owned by such person or group by the sum of the 182,981,824 shares of common stock outstanding on January 31, 2018, plus the number of shares of common stock that such person or group has the right to acquire within 60 days of January 31, 2018.
(2) Includes 13 shares of common stock, which Dr. Simpson has the right to acquire upon exercise of outstanding options exercisable within 60 days of January 31, 2018.
(3) Includes 7 shares of common stock, which Mr. Purpura has the right to acquire upon exercise of outstanding options exercisable within 60 days of January 31, 2018.
(4) Includes 5 shares of common stock, which Ms. Keck has the right to acquire upon exercise of outstanding options exercisable within 60 days of January 31, 2018, and 4 shares held in a joint account with her spouse.
(5) Dr. Pedder has not yet received an equity grant.
(6) Includes 5 shares of common stock, which Dr. Stoll has the right to acquire upon exercise of outstanding options exercisable within 60 days of January 31, 2018
(7) Includes 10 shares of common stock, which Mr. Rueckert has the right to acquire upon exercise of outstanding options exercisable within 60 days of January 31, 2018.
(8) Includes 10 shares of common stock, which Dr. Taglietti has the right to acquire upon exercise of outstanding options exercisable within 60 days of January 31, 2018.
(9) Includes 55 shares of common stock, which certain directors and executive officers have the right to acquire upon exercise of outstanding options exercisable within 60 days of January 31, 2018.
